Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.